Cyclomune
developed to support ocular surface inflammation to alleviate dry eye symptoms.
Strengths: 0.05 · 0.1%
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Ikervis; Verkazia
- Therapeutic class
Immunosuppressant
- Pharmacological class
Calcineurin Inhibitor
- Contraindications
active ocular infection
- Minor side effects
ocular burning; conjunctival hyperaemia
- Moderate side effects
epiphora; eye pain
- Serious side effects
corneal ulceration — requires immediate medical attention
- Dosage forms
Eye drops, emulsion
- Administration route
Ocular use
- Patient summary
developed to support ocular surface inflammation to alleviate dry eye symptoms.
- Prescription status
POM
- Manufacturer
Sun Pharma
- Onset Time
4–8 weeks
- Duration
Long-term
- Storage instructions
Store in a cool, dry place.
- Age restrictions
18 years and over
- Pregnancy and breastfeeding
Pregnancy: consult doctor. Breastfeeding: caution advised.
Precautions and warnings
remove contact lenses before application; use caution in patients with history of herpes keratitis
Mechanism of action
Acts as an immunomodulator by inhibiting T-lymphocyte activation, which helps reduce ocular inflammation.
Cyclomune
developed to support ocular surface inflammation to alleviate dry eye symptoms.
Editorial Notes
- Active ingredient(s): Cyclosporine
- Listed indication(s): Keratoconjunctivitis Sicca
Usually available as
- 3 bottles - 0.05 %1521-0-05-pct-17553
- 2 bottles - 0.1 %1521-0-1-pct-17547